Incontinence Device Draft Guidance Suggests One-Year Randomized Studies
This article was originally published in The Gray Sheet
Executive Summary
Randomized, controlled trials are the least burdensome means of collecting data to demonstrate safety and effectiveness of urinary incontinence devices, according to a Sept. 19 FDA 1draft guidance
You may also be interested in...
Regulatory News In Brief
Medtronic pulls YouTube ad: In response to a Dec. 3 1citizen petition from consumer advocacy group the Prescription Project, Medtronic requested a video ad for its Prestige cervical disc, posted on YouTube and other Web sites by video production firm VNR-1 Communications, be removed from the Internet. The ad no longer appears on YouTube, Medtronic confirms in a Dec. 12 2letter to FDA, posted online Dec. 30. The Prescription Project said Medtronic, Stryker and Abbott advertised products online without legally mandated disclosures of potential risks and side effects (3"The Gray Sheet" Dec. 8, 2008, p. 7). Medtronic says it is reviewing the circumstances surrounding the posting by VNR, but does not plan to run any "curative ads," as they would "only add confusion to the matter.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.